Phenylpropanolamine
- Generic Name
- Phenylpropanolamine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13NO
- CAS Number
- 14838-15-4
- Unique Ingredient Identifier
- 33RU150WUN
- Background
Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
- Indication
For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.
- Associated Conditions
- Allergy-Induced Respiratory Symptoms, Bronchitis, Common Cold, Cough, Nasal Congestion, Rhinorrhoea, Excess mucus or phlegm
Vascular Photobiomodulation Shows Promise for Post-COVID-19 Headache Relief
• A randomized, double-blind clinical trial evaluated vascular photobiomodulation (VPBM) for relieving persistent post-COVID-19 headache, showing gradual pain reduction in the treatment group.
• Sham VPBM also improved pain sensation, potentially due to musculoskeletal and emotional factors mitigated by the relaxing treatment environment.
• VPBM may modulate inflammation and stimulate mitochondrial components, leading to systemic benefits and improved quality of life for patients.
• The study highlights the need for further research to optimize VPBM protocols and address limitations such as sample size and follow-up duration.
CervoMed's Neflamapimod Fails to Meet Endpoints in Phase 2b DLB Trial Due to Suboptimal Drug Exposure
• CervoMed's RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies (DLB) did not meet its primary or secondary endpoints.
• Initial analysis suggests that target plasma drug concentrations were not achieved during the double-blind phase, impacting trial results.
• The company is analyzing clinical and pharmacokinetic data and will provide an update after the open-label extension data becomes available in late Q2 2025.
• Despite the setback, neflamapimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath